1. Home
  2. COMP vs MIRM Comparison

COMP vs MIRM Comparison

Compare COMP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Inc.

COMP

Compass Inc.

HOLD

Current Price

$13.12

Market Cap

4.9B

Sector

Technology

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$94.50

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COMP
MIRM
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.2B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
COMP
MIRM
Price
$13.12
$94.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
11
Target Price
$11.89
$97.55
AVG Volume (30 Days)
23.5M
725.7K
Earning Date
02-17-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,642,200,000.00
$471,794,000.00
Revenue This Year
$25.30
$54.25
Revenue Next Year
$11.92
$21.09
P/E Ratio
N/A
N/A
Revenue Growth
24.27
53.66
52 Week Low
$5.66
$36.88
52 Week High
$13.53
$96.13

Technical Indicators

Market Signals
Indicator
COMP
MIRM
Relative Strength Index (RSI) 70.47 72.38
Support Level $12.64 $89.47
Resistance Level $13.50 $93.70
Average True Range (ATR) 0.63 4.17
MACD 0.10 0.77
Stochastic Oscillator 87.65 89.83

Price Performance

Historical Comparison
COMP
MIRM

About COMP Compass Inc.

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: